Focus on Lipids Care

Back to articles

Ezetimibe: Add-on therapy improves some cardiovascular outcomes

KEY POINT

The use of combination therapy with ezetimibe/simvastatin (Vytorin—Merck) in high-risk patients recently hospitalized with an acute coronary syndrome (ACS) resulted in a greater risk reduction of major cardiovascular (CV) events compared with simvastatin monotherapy, according to results of the IMPROVE–IT trial.

SOURCES

Cannon CP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.

Jarcho JA et al. Proof that lower is better—LDL cholesterol and IMPROVE-IT [Editorial]. N Engl J Med. 2015;372:2448–50.